Iterum Therapeutics PLC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Iterum Therapeutics plc Director Michael W. Dunne acquired 6,000 ordinary shares at $0.3652 per share, increasing his beneficial ownership.
Iterum Therapeutics plc Director Michael W. Dunne plans to acquire 15,000 ordinary shares at $0.7236 each, increasing his direct holdings to 235,001 shares.
Iterum Therapeutics plc's Chief Commercial Officer, Christine Coyne, was granted 200,000 share options with an exercise price of $0.97, vesting over four years.
Director Ronald Hunt reports the exchange of senior subordinated notes for ordinary shares of Iterum Therapeutics, marking the end of the exchange period for these notes.
Director Michael W. Dunne reports purchasing shares and warrants in Iterum Therapeutics' recent rights offering.
Corey N. Fishman, CEO of Iterum Therapeutics plc, reports the acquisition of ordinary shares and warrants through the company's rights offering.
Director Ronald Hunt reports exercising subscription rights through affiliated entities in Iterum Therapeutics' recent rights offering.